FutureChemistry
FutureChemistry | Flow Chemistry technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
N/A | Spinout | ||
| Total Funding | 000k | ||
Related Content
FutureChemistry operates as a specialized boutique consultancy focused on the radiopharmaceutical industry. The firm provides services to assist companies in the development and production of radiopharmaceuticals and radionuclides for nuclear medicine.
The company is steered by CEO Pieter Nieuwland, PhD, whose background in chemistry provides a foundation for translating small-scale chemical reactions into automated processes for medical isotope processing and radiopharmaceutical manufacturing. He is joined by COO Dion van der Born, PhD, who brings expertise in radiochemistry, specifically in developing methodologies for radiolabelling drugs for biological evaluation. This leadership team combines practical experience in process automation with specialized knowledge in radiochemical development.
FutureChemistry's business model is centered on providing custom, client-focused solutions. A key operational principle is its independence from equipment manufacturers, allowing it the flexibility to source components from any supplier or to design and build equipment in-house to meet specific client requirements. The company explicitly states that it does not claim intellectual property developed during client projects, a significant value proposition for its partners.
The service portfolio is comprehensive, covering the entire process of industrializing radiopharmaceuticals. Core offerings include the design and engineering of custom equipment, such as synthesis modules, and the development and automation of new or existing processes to enhance efficiency. Furthermore, the firm provides commissioning, qualification, and validation services to ensure that radiopharmaceutical processes are implemented smoothly and meet regulatory standards.
Keywords: radiopharmaceutical process, nuclear medicine, radiochemistry consultancy, medical isotopes, process development, process automation, equipment design, radiochemical manufacturing, radionuclide production, Pieter Nieuwland, Dion van der Born, radiolabelling, synthesis modules, process validation, cGMP, custom solutions, pharmaceutical engineering